MOUNTAIN VIEW, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Aerogen, Inc. today announced that Mauro J. Folena has joined Aerogen's executive management team as Vice President of Operations. Mr. Folena will provide leadership for all manufacturing activities and oversee Aerogen's product development process and engineering activities.
Before joining Aerogen, Mr. Folena was Director of Operations for Honeywell International where he led a Pressure Sensor manufacturing operation. Prior to his years at Honeywell, Mr. Folena's work experience includes 21 years with National Semiconductor in the field of equipment engineering, and development of high volume manufacturing operations.
"I am delighted to welcome Mauro to our team. His technical expertise, gained from years of practical experience, will be extremely beneficial to Aerogen as we develop and pursue the many commercial opportunities that exist for our company," said Jane E. Shaw, Ph.D., Chairman and Chief Executive Officer.
Mr. Folena received a B.S. in Information Systems Management at the University San Francisco and is a Certified Instructor from the Japan Institute of Plant Maintenance in Total Productive Maintenance.
Aerogen, a specialty pharmaceutical company, develops products based on its OnQ(R) Aerosol Generator technology to improve the treatment of respiratory disorders in the acute care setting. Aerogen currently markets the Aeroneb(R) Professional Nebulizer System for use in hospitals. Aerogen has presented the results of its first Phase 2 clinical study evaluating delivery of aerosolized amikacin for the treatment of ventilator-associated pneumonia; an additional Phase 2 study is currently underway. Following amikacin, additional drug products targeting improved respiratory therapy in the acute care setting are in the feasibility and pre-clinical stages of development. In the U.S., Aerogen has commercialized the Aeroneb(R) Go Nebulizer for home use through its commercial partner, Evo Medical Solutions, Inc. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Aerogen is headquartered in Mountain View, California, with a campus in Galway, Ireland. For more information, visit http://www.aerogen.com/.
To the extent any statements made in this release relate to information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside of Aerogen's control and other uncertainties, and are subject to various risk factors that could cause Aerogen's actual results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the need for additional funding, the inherent risks of product development, clinical outcomes, regulatory risks and risks related to proprietary rights, market acceptance and competition, and are described in Aerogen's reports and other filings with the U.S. Securities and Exchange Commission, including Aerogen's Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission ("SEC") on April 14, 2004 and Aerogen's Quarterly Report filed on Form 10-Q for the quarter ended September 30, 2004 filed with the SEC on November 15, 2004. Aerogen does not undertake any obligation to update forward-looking statements.